FDA panel examines HIV microbicides
BY Advocate.com Editors
August 21 2003 11:00 PM ET
A Food and Drug Administration panel convened Wednesday in Washington, D.C., to discuss ways to test HIV microbicides, compounds developed to help prevent HIV infection through sexual contact. The panel examined such issues as how long an experimental microbicide trial should be, what data would need to be collected to prove the effectiveness of a microbicide, and whether the trials should compare the effectiveness of microbicides to condom use and/or a placebo.
"There is extreme urgency to develop a topical microbicide rationally and get it on the market as soon as possible," Debra Birnkrant, director of the FDA's division of antiviral drugs, told the Dow Jones News Service. "We've been wrestling with these issues for a few years now."
The panel did not reach any consensus on the issues and agreed to meet later this year for further discussion. Panel members did note that the first experimental microbicide to undergo clinical trials would likely face stringent testing and data-gathering requirements. Microbicide researchers hope to have an effective product on the market by 2007.
- Op-ed: Two and a Half Men Introduces Trans Character, Manages to Stay Respectful
- WATCH: The Best of LGBT Chorus Holiday Music
- WATCH: Obama Invokes LGBT Rights in Mandela Eulogy
- Salvation Army 'Does Not Consider Homosexual Orientation a Sin'
- WATCH: The 12 Gayest Holiday Spectaculars Ever!
- New Gay U.S. Ambassador Meets With Dominican President
- Women Emily Rios' Lesbian Character on The Bridge Upped to Series Regular 2 hours 39 min ago
- Media Russia Expert to Offer Political Commentary During Olympics 7:56 PM
- Travel In-Flight Cellphone Conversations: Dream or Nightmare? 7:48 PM
- Politics New Gay U.S. Ambassador Meets With Dominican President 7:08 PM
- Latest News NBC To Spotlight Russia’s Human Rights Abuses During Olympics 6:11 PM
- Couples/Personal Finances The Financial Effects of DOMA: Filing Taxes 5:56 PM
- Couples/Personal Finances Examining Employee Benefits in the Wake of DOMA’s Overturn 5:38 PM